11 October 2024 | Friday | News
Picture Courtesy | Public Domain
New MammoScreen® AI delivers a comprehensive suite of features including breast density and pre-reporting, creating the ultimate radiologist companion.
Therapixel, maker of MammoScreen, announces that it has received two new FDA 510(k) clearances, resulting in the release of its most comprehensive breast cancer screening AI. With a set of powerful new features, MammoScreen goes beyond suspicious lesion detection and characterization and incorporates AI into all areas of the breast imaging workflow.
The new version of MammoScreen maintains the consistent and actionable MammoScreen Score™ while increasing the radiologist's sensitivity and specificity. This newly cleared full AI-suite provides the following powerful new features which will considerably improve radiologists' workflow:
These new features, now available for clinical use, will help radiologists read faster and more confidently, thus delivering results to women in a more timely and assured manner. The new release of MammoScreen helps make the entire organization better.
"Therapixel has consistently empowered radiologists to excel, ensuring women receive reassurance faster and with greater confidence," said Matthieu Leclerc-Chalvet, CEO of Therapixel. "These major clearances and releases elevate MammoScreen to a comprehensive suite, assisting radiologists at every step of the breast cancer screening workflow, and providing a service unmatched in the industry. With these new features, radiologists can double their reading time savings compared to the previous version. Radiologists will appreciate the reduced fatigue, administrators the improved efficiency and care consistency, and the IT team the seamless one-time installation. We're proud to launch this new version of MammoScreen, once again delivering unparalleled value to radiologists and patients."
© 2024 Biopharma Boardroom. All Rights Reserved.